mCPP

mCPP is covered structurally, rather than expressly named, by Anlage II Z 7 of the Neue-Psychoaktive-Substanzen-Verordnung, which has encompassed compounds derivable from 1-phenylpiperazine with the listed substituents since 1 January 2012. Under section 4(1) of the Neue-Psychoaktive-Substanzen-Gesetz, production, import, export, supply, or procurement for another person is punishable only when undertaken both with intent to obtain an advantage and with intent that another person or a third party use the substance to achieve a psychoactive effect. That offence carries up to two years' imprisonment, or one to ten years if it causes death or serious bodily injury to a larger number of people. Simple possession for personal use is not a standalone criminal offence under section 4, although section 5 permits confiscation unless lawful use and safeguards against psychoactive use are established.

The Royal Decree of 6 September 2017 covers mCPP through the generic phenylpiperazine definition in Annex IVa, piperazine class 6b, which encompasses its 3-chloro substituent. Since 26 September 2017, Article 6 has required prior authorization for possession, acquisition, import, export, transport, manufacture, production, sale, supply, and delivery, subject to licensed and professional exceptions.

mCPP is listed by exact name as 1-(3-clorofenil)piperazina (mCPP) in Lista F2 of Portaria SVS/MS nº 344, de 12 de maio de 1998. It has been included in Lista F2 since 5 November 2008. Production, manufacture, import, export, commerce, and use are prohibited, except for activities by authorized bodies and institutions conducted strictly for medical and scientific research; unauthorized acquisition, possession, storage, transport, sale, delivery, and supply are also controlled. Anvisa-authorized establishments may stock analytical standards for laboratory analysis, teaching, or research, and import or export authorization is not required for an mCPP analytical standard containing no more than 500 mg of controlled active substance per unit.

mCPP is listed by its exact name, 1-(3-Chlorophenyl)piperazine, and CAS number 6640-24-0 as item 101 in the 2025 Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances. It has been controlled since 1 October 2015. Production, purchase or sale, transport, use, storage, import, and export are prohibited, subject to separate rules for scientific research, experiments, standards and reference materials, and pharmaceutical-production intermediates.

mCPP (1-(3-chlorphenyl)piperazin) is listed at item 273 of List B in Bekendtgørelse om euforiserende stoffer, BEK nr. 405 af 26. marts 2026. List B substances may be used only for medical or scientific purposes, and possession and other dealings are permitted only under the order's prescription, institutional, pharmacy, or Danish Medicines Agency authorization rules. mCPP has been included in List B since 3 December 2005.

m-CPP, chemically 1-(3-Chlorphenyl)piperazin, is listed in Anlage II of the Betäubungsmittelgesetz as a marketable but non-prescribable narcotic. It was first added with effect from 1 March 2007 for one year and was subsequently placed permanently in Anlage II. Under § 29(1) BtMG, unauthorized cultivation, production, trade, import, export, sale, supply, acquisition, and procurement are punishable, as is possession without written authorization for acquisition, by imprisonment for up to five years or a fine. Under § 29(5) BtMG, a court may refrain from punishment in a personal-use case involving a small quantity.

mCPP is listed by its exact chemical name, CPP: 1-(3-chlorophenyl)piperazine, in Table A of Greece's current controlled-substance tables. Under Article 2 of Law 4139/2013, production, possession, transport, storage, supply, processing, circulation, and trafficking mediation involving Table A substances are reserved exclusively to the State; import and export require authorization from the Ministry of Health.

mCPP, identified as meta-chlorophenylpiperazine [1-(3-chlorophenyl)piperazine], is listed at row 74 of the P1 psychotropic-substances schedule in Annex 2 to 78/2022. (XII. 28.) BM rendelet az ellenőrzött anyagokról. Under section 3(1) of 66/2012. Korm. rendelet, production, manufacture, import, export, acquisition, distribution, storage, possession, handover, and use require an activity licence, subject to the decree's stated exceptions. Section 4(7) permits authorisation of P1 psychotropic-substance use only for research or industrial purposes, apart from the statutory exception it cites. mCPP has been listed by exact name in the P1 schedule since 22 December 2005; the current decree took effect on 1 January 2023.

mCPP, under the name 1-(3-chlorophenyl)piperazine and its salts, is designated as a narcotic by Article 1, item 31 of 麻薬、麻薬原料植物、向精神薬、麻薬向精神薬原料等を指定する政令（平成二年政令第二百三十八号）. The designation took effect on 13 October 2006. Import, manufacture, transfer, acquisition, and possession are restricted to licensed or otherwise authorized persons under the Narcotics and Psychotropics Control Act, subject to statutory exceptions.

mCPP is listed by exact name as 1-(3-chlorophenyl)piperazine in Lithuania's I sąrašas under the 1971 Convention Schedule I subsection, effective from 15 July 2006. Lawful circulation, including production, processing, acquisition, sale, possession, supply, domestic transport, import, and export, is prohibited except for the specified medicinal-product, scientific-research, government, and reference-material uses.

mCPP is listed as m-Chlorphenylpiperazin (m-CPP) in Annex 5, Verzeichnis d, of the Betäubungsmittelverzeichnisverordnung; the instrument also cross-references 1-(3-Chlorphenyl)piperazin to the same entry. Verzeichnis d comprises prohibited controlled substances, so cultivation, import, manufacture and placing on the market are generally forbidden, although the Federal Office of Public Health may authorize dealings for certain purposes under exceptional permit rules.

1-(3-Chlorophenyl)piperazine (mCPP) has been a Class C controlled drug throughout the United Kingdom since 23 December 2009. It is covered by the generic definition in Schedule 2 Part III paragraph 1(ca) of the Misuse of Drugs Act 1971 for compounds structurally derived from 1-phenylpiperazine by aromatic-ring substitution with a halide. The current Schedule 4 Part I of the Misuse of Drugs Regulations 2001 also names mCPP exactly for England, Wales and Scotland, while the Northern Ireland regulations contain the parallel Schedule 4 Part I entry. Its controlled status applies to possession, possession with intent to supply, production, supply, and offering to supply; Schedule 4 Part I does not exempt possession.

mCPP, also known as 1-(3-chlorophenyl)piperazine, is not listed in federal Schedules I through V under 21 CFR Part 1308 or as a List I or List II regulated chemical. Its unscheduled status does not preclude case-specific treatment under the Controlled Substance Analogue Enforcement Act, which requires the substance to satisfy the statutory definition and exclusions and applies Schedule I treatment only to the extent that the substance is intended for human consumption. No federal scheduling rule or judicial opinion specifically classifies mCPP as a controlled-substance analogue of BZP.